Myocardial perfusion PET is effective for diagnosing CAD

Although myocardial perfusion PET, using either cyclotron-produced ammonia or generator-produced rubidium 82, has reported excellent diagnostic capabilities in the detection of coronary artery disease (CAD) in individual studies, the technique is not widely used in practice, which may be driven by cost and availability or by unawareness of performance, according to the April issue of Academic Radiology.

According to Kiran R. Nandalur, MD, department of radiology, University of Michigan Health System, in Ann Arbor, Mich., and colleagues, the purpose of the study was to conduct an evidence-based evaluation of PET in the diagnosis of CAD.

Kiran and co-researchers examined studies from January 1977 to July 2007 using MEDLINE and EMBASE. A study was included if it (1) used PET as a diagnostic test for CAD and (2) used catheter x-ray angiography as the reference standard (≥50 percent diameter stenosis). Analysis was performed on a subject and coronary territory level.

Nineteen studies (1,442 patients) met the inclusion criteria. The results showed that on a patient level, PET demonstrated a sensitivity of 0.92 and specificity of 0.85, with a positive likelihood ratio (LR+) of 6.2 and negative likelihood ratio (LR_) of 0.11. On a coronary territory level (1,130 patients), PET showed a sensitivity of 0.81 and specificity of 0.87,with an LR+ of 5.9 and an LR_ of 0.19 .

Researchers concluded that PET demonstrates “excellent diagnostic properties in the diagnosis of CAD, especially at the patient level. The capabilities appear superior to those reported in meta-analyses for perfusion imaging with Tl-201 and sestamibi, or anatomical imaging with coronary MDCT angiography or MRA. Given that previous studies have found PET to be cost-effective and the current findings of excellent sensitivity and specificity, the modality should be more widely considered as an initial test in the diagnosis of CAD.”

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.